Zoledronic acid affects men and women similarly in increasing bone mass after hip fracture

J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21

Zoledronic acid has no continued benefit beyond 6 years for osteoporosis

J Bone Miner Res. 2015 May;30(5):934-44.

Zoledronic acid improves health-related quality of life in patients with hip fractures

Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20

Two Infusions of Zoledronic Acid Reduce Femoral BMD Loss after THA Measured over 2 years

J Arthroplasty. 2013 Apr;28(4):671-5. doi: 10.1016/j.arth.2012.08.007. Epub 2012 Nov 8

Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis

J Int Med Res. 2013 Jun;41(3):697-704. doi: 10.1177/0300060513480917. Epub 2013 May 13

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

Zoledronic acid increases BMD at tibial epiphysis, but not tibial diaphysis

Maturitas. 2014 Mar;77(3):287-93

The effect of 3 versus 6 years of zoledronic acid treatment on femoral neck-BMD

J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494

Postoperative zoledronic acid has no effect on healing after Lapidus arthrodesis and Akin osteotomy

J Int Med Res. 2018 Aug;46(8):3251-3261. doi: 10.1177/0300060518760128

Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082

Efficacy of zoledronic acid following PLIF in patients with osteoporosis

Osteoporos Int. 2016 Apr;27(4):1469-76

Health-related QoL in osteoporotic women improved with zoledronic acid infusions

Bone. 2011 Jun 1;48(6):1298-304. doi: 10.1016/j.bone.2011.03.719. Epub 2011 Mar 21